NCT01043276View on ClinicalTrials.gov

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Asthma
Interventions
DRUG

Treatment A

PF-00258210 220 µg using inhaler A

DRUG

Treatment B

PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A

DRUG

Treatment C

PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A

DRUG

Treatment D

PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A

DRUG

Treatment E

PF-00258210 220 µg using inhaler B

Trial Locations (1)

188770

Pfizer Investigational Site, Singapore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01043276 - A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355 | Biotech Hunter | Biotech Hunter